Nab-Paclitaxel-Based Systemic Approach to Achieving Complete Remission for Relapsed Stage III Endometrial Carcinoma: Insights From the Indian Subcontinent

TL;DR

A 65-year-old woman with relapsed endometrial cancer achieved complete remission using a nab-paclitaxel and carboplatin treatment.

Contribution

The paper highlights a successful nab-paclitaxel-based treatment for relapsed high-risk endometrial carcinoma.

Findings

A 65-year-old patient achieved complete remission after relapse using Taxonab 300mg and carboplatin 450mg.

Nab-paclitaxel-based therapy is suggested as a promising strategy for inoperable, high-risk endometrial cancer relapses.

The case emphasizes the potential of nab-paclitaxel in treating difficult-to-manage endometrial carcinoma cases.

Abstract

Endometrial adenocarcinoma (EC) is a common type of cancer in women that starts in the lining of the uterus. It usually affects women following menopause but can also occur in younger women. There are different types of EC based on how the cells look under a microscope and their molecular characteristics. EC is generally divided into two main groups: Type I, which is linked to estrogen and mainly consists of low-grade cells, is more common and usually has a better outcome; and Type II, which is not related to estrogen, consists of high-grade cells, is less common, and typically has a worse prognosis. This case report presents a comprehensive examination of the clinical course of a 65-year-old female patient who achieved complete remission following a relapse of high-risk EC through a unique therapeutic approach involving Taxonab 300mg/carboplatin 450mg. The case report underscores the significance of investigating nab-paclitaxel-based interventions as a promising strategy for improving outcomes in patients facing the challenging scenario of inoperable, high-risk EC relapses.

Figures